|
Technology Licensing Opportunities
It is the general policy of BBRI that the results of research of its staff and employees should be made promptly, freely and widely available to other research workers and to the public. In most instances, this purpose is best served by publication of all information concerning the research and its practical applications. However, in some cases, the application of research results can be speeded by seeking patent protection for inventions when appropriate and by forming partnership with industry to speed the development of the fruits of research into procedures or products that can improve the diagnosis and management of disease. The importance of such technology transfer to the public interest was recognized by the US Congress through passage of the Bayh-Dole legislation in 1980. Accordingly, BBRI is sincerely interested in exploring partnerships with companies that will complement its basic research programs and enable the discoveries of its scientists to move from the research bench to the clinic as rapidly as possible. BBRI also welcomes collaborations with scientists from academic and other non-profit institutions.
For further information please contact:
Mr. Todd S. Keiller
Director, Technology Affairs
Boston Biomedical Research Institute
64 Grove Street
Watertown, MA 02472
Direct Phone: 508-497-2497
BBRI Phone: 617-658-7786
Fax: 508-497-0733
Email: keiller@bbri.org
PATENTS:
|
Invention
|
Inventor |
Patent |
Status |
| Compositions and Methods for Binding or Inactivating Grehlin |
Raso |
Pending |
|
| Methods for Identifying Modulators of Hedgehog Autoprocessing |
Paulus, Emerson & Ai |
Pending |
|
| Methods and Compositions for Specific Inhibition of Protein Splicing by Small Molecules for the Treatment of Tuberculosis |
Paulus |
Pending |
|
| Methods for Delaying or Inducing Labor |
Morgan & Li |
Pending |
|
| Leptin Peptide Antagonists for Cancer, Implantation, Preeclampsia, and Endometriosis |
Gonzalez & Leavis |
Pending |
|
| Methods for Preventing or Reducing Ischemia/Reperfusion Induced Myocardial Cell Death (PUMA) |
Erhardt |
Pending |
|
| Inhibition of FGF Signaling via Sulf1 |
Emerson |
Pending |
|
Anti-idiotypic Vaccines to Elicit Catalytic Antibodies
Alternative approach for obtaining catalytic antibodies that does not require knowledge of enzyme active sites or modification of polypeptides. Potential applications to the in vivo generation of catalytic antibodies for therapeutic purposes. |
Raso & Paulus |
U.S.#6,140,091 |
Licensed |
Immunological Control of Beta-Amyloid Levels
Vaccines to reduce the size and number of amyloid plaques or delay their appearance in the brain. (Alzheimer's disease applications) |
Raso |
U.S. #6,582,945
U.S. #6,872,554 |
Licensed |
Bispecific Monoclonal Antibodies
Chemical methodology to prepare bispecific antibodies. Broad applications in therapeutics, diagnostics, electrodes, molecular microcircuits. |
Paulus |
U.S.#4,444,878
U.S.#5,292,668
U.S.#5,523,210
Foreign patents |
Licensed |
Human carcinoma antigen (HCA), HCA antibodies, HCA immunoassays and methods of imaging |
Codington |
U.S.#5,545,532 |
Licensed |
Antibodies to human carcinoma antigen |
Codington |
U.S.#5,693,763 |
Licensed |
Human carcinoma antigen |
Codington |
U.S.#5,808,005 |
Licensed |
Cellular Uptake of Modified Peptides
Method to introduce peptides into cells and to covalently cross-link peptides to their intracellular targets. |
Coleman |
U.S.#5,736,394 |
|
Collagen Extracted from Collagen-Containing Tissue
Method for collagen extraction. Collagen product may be used as cell growth matrix, synthetic skin, dressing for wounds, or membranes. |
Davidson |
U.S.#4,983,721
U.S.#5,064,941 |
|
Method for Delivering Functional Domains of Diphtheria Toxin To a Cellular Target |
Raso & Sheldon |
U.S.#5,830,478 |
|
Hybrid Reagents Capable of Selectively Releasing Molecules into Cells
Hybrid antibody system to rapidly release a toxin inside a cell. |
Raso |
U.S.#5,501,854
U.S.#5,603,931
U.S.#5,599,908
Foreign Patents |
|
Heat Shock Protein Induction and Applications
Method of inducing Hsp72 production using a proteasome inhibitor. |
Sherman |
U.S.#6,096,711 |
|
|
Method for Screening of Chemical Compounds and Genes that Reverse Polyglutamine Toxicity |
Sherman (with MIT) |
Pending |
|
|
Methods and Compositions Relating to Anthrax Pathogenesis |
Bohm (with U. of Chicago) |
Pending |
|
|
Method for Generating Split, Non-transferable Genes that are able to Express an Active Protein Product
Protein splicing in trans to express a protein as two inactive fragment that can be constituted by protein splicing to produce a functional enzyme. |
Paulus (with NE Biolabs) |
Pending |
Licensed |
|
|
|
|
| |
|
|
|
|
